Twin Capital Management Inc. Has $473,000 Stock Holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Twin Capital Management Inc. cut its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 74.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,510 shares of the biopharmaceutical company’s stock after selling 4,400 shares during the period. Twin Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $473,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Cornerstone Advisors Inc. boosted its position in Regeneron Pharmaceuticals by 3.7% during the first quarter. Cornerstone Advisors Inc. now owns 842 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 30 shares during the last quarter. Rehmann Capital Advisory Group boosted its position in Regeneron Pharmaceuticals by 31.3% during the first quarter. Rehmann Capital Advisory Group now owns 210 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 50 shares during the last quarter. Public Employees Retirement Association of Colorado boosted its position in Regeneron Pharmaceuticals by 0.4% during the second quarter. Public Employees Retirement Association of Colorado now owns 14,937 shares of the biopharmaceutical company’s stock valued at $4,675,000 after purchasing an additional 56 shares during the last quarter. JGP Global Gestao de Recursos Ltda. raised its stake in Regeneron Pharmaceuticals by 10.6% in the first quarter. JGP Global Gestao de Recursos Ltda. now owns 606 shares of the biopharmaceutical company’s stock valued at $249,000 after buying an additional 58 shares during the period. Finally, Sumitomo Mitsui Asset Management Company LTD raised its stake in Regeneron Pharmaceuticals by 1.1% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 5,420 shares of the biopharmaceutical company’s stock valued at $2,225,000 after buying an additional 59 shares during the period. 66.97% of the stock is owned by hedge funds and other institutional investors.

Several research firms have issued reports on REGN. ValuEngine lowered Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, June 7th. Cowen restated a “hold” rating and issued a $353.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, July 29th. UBS Group dropped their price objective on Regeneron Pharmaceuticals from $480.00 to $440.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Robert W. Baird upgraded Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $410.00 price objective on the stock in a research note on Wednesday, August 7th. Finally, Credit Suisse Group dropped their price objective on Regeneron Pharmaceuticals from $333.00 to $325.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $398.25.

Shares of NASDAQ REGN traded up $3.74 during trading hours on Friday, reaching $296.85. 730,200 shares of the stock were exchanged, compared to its average volume of 733,513. The firm has a market capitalization of $32.19 billion, a price-to-earnings ratio of 14.99, a P/E/G ratio of 1.34 and a beta of 1.15. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.11 and a current ratio of 3.88. Regeneron Pharmaceuticals Inc has a 52 week low of $287.66 and a 52 week high of $442.00. The stock’s fifty day simple moving average is $304.13 and its 200 day simple moving average is $350.53.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $5.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.60 by $0.69. The company had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.80 billion. Regeneron Pharmaceuticals had a return on equity of 25.79% and a net margin of 28.59%. The firm’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter last year, the company earned $5.45 earnings per share. Research analysts predict that Regeneron Pharmaceuticals Inc will post 19.22 EPS for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: How to Use the New Google Finance Tool

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.